Chance favors the prepared mind--from serendipity to rational drug design.
暂无分享,去创建一个
[1] Hans-Joachim Böhm,et al. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads , 1992, J. Comput. Aided Mol. Des..
[2] George de Stevens. Serendipity and structured research in drug discovery. , 1986 .
[3] Thomas Lengauer,et al. Computational methods for biomolecular docking. , 1996, Current opinion in structural biology.
[4] T. E. Rogers,et al. Chapter 20. Cell Adhesion Integrins as Pharmaceutical Targets , 1996 .
[5] Thomas Lengauer,et al. Time-efficient flexible superposition of medium-sized molecules , 1997, German Conference on Bioinformatics.
[6] C. Ganellin,et al. Medicinal Chemistry: The Role of Organic Chemistry in Drug Research , 1985 .
[7] A I Graul. The year's new drugs. , 2001, Drug news & perspectives.
[8] Thomas Lengauer,et al. Structure Based Drug Design , 2005 .
[9] Gerhard Klebe,et al. What Can We Learn from Molecular Recognition in Protein–Ligand Complexes for the Design of New Drugs? , 1996 .
[10] R. Shader,et al. Burger's Medicinal Chemistry and Drug Discovery: , 1995 .
[11] Carlos Alberto Brebbia,et al. Basic principles and applications , 1984 .
[12] R. Babine,et al. MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .
[13] J. Condra,et al. Clinically effective HIV-1 protease inhibitors , 1997 .
[14] J. Swift,et al. Gulliver's travels : a voyage to Laputa , 1957 .
[15] H. Hamm,et al. GTPase mechanism of Gproteins from the 1.7-Å crystal structure of transducin α - GDP AIF−4 , 1994, Nature.
[16] P J Goodford,et al. Drug design by the method of receptor fit. , 1984, Journal of medicinal chemistry.
[17] H J Böhm,et al. Computational tools for structure-based ligand design. , 1996, Progress in biophysics and molecular biology.
[18] W G Laver,et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. , 1997, Journal of the American Chemical Society.
[19] David E. Clark,et al. A comparison of heuristic search algorithms for molecular docking , 1997, J. Comput. Aided Mol. Des..
[20] A. Gilman,et al. Aluminum: a requirement for activation of the regulatory component of adenylate cyclase by fluoride. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[21] C. E. Peishoff,et al. Discovery of Potent Nonpeptide Vitronectin Receptor (αVβ3) Antagonists , 1997 .
[22] J. S. Dixon,et al. Evaluation of the CASP2 docking section , 1997, Proteins.
[23] Hans-Joachim Böhm,et al. Towards the automatic design of synthetically accessible protein ligands: Peptides, amides and peptidomimetics , 1996, J. Comput. Aided Mol. Des..
[24] B. E. Evans,et al. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[25] Gerd Folkers,et al. Ligand-protein interactions and molecular similarity , 1998 .
[26] Royston M. Roberts,et al. Serendipity: Accidental Discoveries in Science , 1989 .
[27] C. Beddell,et al. The Design of drugs to macromolecular targets , 1992 .
[28] Abby L. Parrill. Recent advances in computer-aided drug design methods , 1997 .
[29] W G Laver,et al. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. , 1997, Journal of medicinal chemistry.
[30] G de Stevens,et al. Serendipity and structured research in drug discovery. , 1986, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[31] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins , 1997, Science.
[32] Hans-Joachim Böhm,et al. The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..
[33] J. C. Dyason,et al. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. , 1996, Journal of medicinal chemistry.
[34] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[35] W. Guida,et al. The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.
[36] Karl A. Walter,et al. ChemInform Abstract: Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR. , 1997 .
[37] P L Myers,et al. Will combinatorial chemistry deliver real medicines? , 1997, Current opinion in biotechnology.
[38] C. E. Peishoff,et al. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. , 1996, Journal of medicinal chemistry.
[39] L. Sternbach. The benzodiazepine story. , 1983, Journal of psychoactive drugs.
[40] J J Baldwin,et al. Application of the three-dimensional structures of protein target molecules in structure-based drug design. , 1994, Journal of medicinal chemistry.
[41] Michael R. Greenberg,et al. Chapter 1 – Theory, Methods, and Applications , 1978 .
[42] Klaus Gubernator,et al. Structure-Based Ligand Design , 1995 .
[43] Hugo Kubinyi,et al. 3D QSAR in drug design : theory, methods and applications , 2000 .
[44] P K Jadhav,et al. De novo design and discovery of cyclic HIV protease inhibitors capable of displacing the active-site structural water molecule. , 1998, Pharmaceutical biotechnology.
[45] H J Böhm,et al. Current computational tools for de novo ligand design. , 1996, Current opinion in biotechnology.
[46] Gerd Folkers,et al. Molecular Modeling, Basic Principles and Applications , 1996 .
[47] J. Briggs,et al. Structure-based drug design: computational advances. , 1997, Annual review of pharmacology and toxicology.
[48] Hans-Joachim Böhm,et al. Structure-Based Ligand Design: Gubernator/Structure-Based , 1998 .
[49] R E Hubbard,et al. Can drugs be designed? , 1997, Current opinion in biotechnology.
[50] Edgar F. Meyer,et al. Backward binding and other structural surprises , 1995 .
[51] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[52] James Samanen,et al. CHAPTER 10. GPIIB/IIIA ANTAGONISTS , 1996 .
[53] F E Cohen,et al. Modeling protein-ligand complexes. , 1996, Current opinion in structural biology.
[54] P. Sprague. Automated chemical hypothesis generation and database searching with Catalyst , 1995 .
[55] D. M. Ryan,et al. Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.
[56] Amedeo Caflisch,et al. Computational combinatorial chemistry for de novo ligand design: Review and assessment , 1995 .
[57] Irwin D. Kuntz,et al. Automated flexible ligand docking method and its application for database search , 1997 .
[58] K. Fowler,et al. Cell adhesion integrins as pharmaceutical targets , 2000 .
[59] G. B. Parks. Serendipity and the Three Princes: From the Peregrinaggio of 1557.Theodore G. Remer , 1968, Renaissance Quarterly.
[60] W. Sneader. Drug prototypes and their exploitation , 1996 .
[61] A. Burger,et al. A Guide to the Chemical Basis of Drug Design , 1983 .